Evidence map›Paper›PMID 35042252›Full record

ReviewZeitschrift fur Gastroenterologie2022

Liver specific, systemic and genetic contributors to alcohol-related liver disease progression.

Bernd Schnabl, Gavin E Arteel, Felix Stickel, Jan Hengstler, Nachiket Vartak, Ahmed Ghallab, Steven Dooley, Yujia Li, Robert F Schwabe

Open access · greenAbstract readReview
In one paragraph

Review in Zeitschrift fur Gastroenterologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Bernd SchnablDepartment of Medicine, University of California San Diego, La Jolla, United States.
Gavin E ArteelDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, United States.
Felix StickelDepartment of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Jan HengstlerSystems Toxicology, Leibniz Research Centre for Working Environment and Human Factors, TU Dortmund University, Dortmund, Germany.
Nachiket VartakSystems Toxicology, Leibniz Research Centre for Working Environment and Human Factors, TU Dortmund University, Dortmund, Germany.
Ahmed GhallabSystems Toxicology, Leibniz Research Centre for Working Environment and Human Factors, TU Dortmund University, Dortmund, Germany.
Steven DooleyDepartment of Medicine II, Section Molecular Hepatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Yujia LiDepartment of Medicine II, Section Molecular Hepatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Robert F SchwabeDepartment of Medicine, Columbia University, New York, United States.
TU Dortmund University · DEUniversity Hospital Heidelberg · DEColumbia University · USLeibniz Research Centre for Working Environment and Human Factors · DEUniversity Hospital of Zurich · CHUniversity of California, San Diego · USUniversity of Pittsburgh · US

Funding

The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVID A GELLER · 2019 to 2026
$10.9M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
The Role of the Intestinal Mycobiome in Alcoholic Liver DiseaseR01AA024726 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2018 to 2026
$3.9M
Microbiome and intestinal innate immune response in alcoholic liver diseaseR01AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHNABL, BERND G. · 2011 to 2020
$3.6M
Biomarkers of Alcoholic HepatitisR01AA028436 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ARTEEL, GAVIN E, BENOS, PANAGIOTIS V · 2020 to 2024
$3.0M
Microbiome and Intestinal Innate Immune Response in Alcoholic Liver DiseaseR37AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2021 to 2026
$2.5M
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCCR01CA262424 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SCHWABE, ROBERT F. · 2021 to 2025
$2.5M
Role of ECM and inflammatory remodeling in alcohol-induced liver and lung damage-diversity supplementR01AA021978 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ARTEEL, GAVIN E · 2014 to 2018
$1.8M
Microbiome as therapeutic target in alcoholic hepatitisU01AA026939 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FOUTS, DERRICK E, SCHNABL, BERND G. · 2018 to 2022
$1.7M
BLRD VA I01 BX004594NCI NIH HHS R01 CA262424NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA020703NIAAA NIH HHS R01 AA021978NIAAA NIH HHS R01 AA024726NIAAA NIH HHS R01 AA028436NIAAA NIH HHS R37 AA020703NIAAA NIH HHS U01 AA026939NIDDK NIH HHS P30 DK120515NIDDK NIH HHS P30 DK120531
6 · The paper itself

Abstract

Alcohol-related liver disease (ALD) impacts millions of patients worldwide each year and the numbers are increasing. Disease stages range from steatosis via steatohepatitis and fibrosis to cirrhosis, severe alcohol-associated hepatitis and liver cancer. ALD is usually diagnosed at an advanced stage of progression with no effective therapies. A major research goal is to improve diagnosis, prognosis and also treatments for early ALD. This however needs prioritization of this disease for financial investment in basic and clinical research to more deeply investigate mechanisms and identify biomarkers and therapeutic targets for early detection and intervention. Topics of interest are communication of the liver with other organs of the body, especially the gut microbiome, the individual genetic constitution, systemic and liver innate inflammation, including bacterial infections, as well as fate and number of hepatic stellate cells and the composition of the extracellular matrix in the liver. Additionally, mechanical forces and damaging stresses towards the sophisticated vessel system of the liver, including the especially equipped sinusoidal endothelium and the biliary tract, work together to mediate hepatocytic import and export of nutritional and toxic substances, adapting to chronic liver disease by morphological and functional changes. All the aforementioned parameters contribute to the outcome of alcohol use disorder and the risk to develop advanced disease stages including cirrhosis, severe alcoholic hepatitis and liver cancer. In the present collection, we summarize current knowledge on these alcohol-related liver disease parameters, excluding the aspect of inflammation, which is presented in the accompanying review article by Lotersztajn and colleagues.

Indexed as

Liver Diseases, AlcoholicLiver NeoplasmsDisease ProgressionEarly Detection of CancerHumansLiver

Identifiers

PMID35042252
PMCPMC8941985
OpenAlexW4205422651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.